Experimental cancer drug trial halted early after 29 patients
NCT ID NCT06287463
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This early-phase trial tested a new drug, DCC-3084, alone or with other treatments, in people with advanced solid tumors linked to MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and check if tumors shrank. It was terminated early after enrolling 29 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
SCRI Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
SCRI HealthONE
Denver, Colorado, 80218, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.